healthcare Theravance Biopharma: Failed Phase 3 Trial, Strategic Review
Theravance Biopharma began a strategic review after a failed Phase 3 trial.
TBPH $874M Clark Street Value
NASDAQ
Theravance Biopharma, Inc.
TBPH
1 article
$874M Market cap · 2026-07-31
healthcare 